Crestor vs Lisinopril: Cost and Access Head-to-Head

What Are These Two Drugs and Why Compare Them?

Rosuvastatin and lisinopril both appear on cardiometabolic treatment lists, which is why patients and prescribers frequently ask about them side by side. They are not substitutes for each other. Rosuvastatin blocks HMG-CoA reductase to reduce hepatic cholesterol synthesis, cutting LDL-C by 45 to 55% at the 20 mg dose. Lisinopril inhibits angiotensin-converting enzyme, reducing arterial resistance and lowering systolic blood pressure by roughly 10 to 15 mmHg at 10 to 40 mg daily.

The comparison matters for three practical reasons: cost planning, understanding why a clinician might prescribe both at once, and clarifying whether a change from one to the other ever makes clinical sense.

How Each Drug Works

Rosuvastatin reduces LDL-C by upregulating hepatic LDL receptors. At 10 mg daily, it produces a mean LDL-C reduction of approximately 46% from baseline, according to FDA prescribing data for the branded product [1]. The drug also modestly raises HDL-C by 8 to 14% and lowers triglycerides by 10 to 35%.

Lisinopril blocks the conversion of angiotensin I to angiotensin II. Less angiotensin II means less vasoconstriction and less aldosterone release. The net result is lower systolic and diastolic blood pressure. Lisinopril also reduces proteinuria, which gives it a separate indication in diabetic nephropathy independent of its blood-pressure effect [2].

Who Gets Each Drug

Rosuvastatin is prescribed when LDL-C is above guideline thresholds or when cardiovascular risk scoring (ACC/AHA Pooled Cohort Equations) places a patient at 7.5% or greater 10-year ASCVD risk. The 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease recommends high-intensity statins for patients with clinical ASCVD regardless of baseline LDL-C [3].

Lisinopril is prescribed for hypertension (Stage 1 at 130/80 mmHg or above per the 2017 ACC/AHA guidelines), heart failure with reduced ejection fraction, and post-myocardial-infarction management. Patients with diabetes and hypertension often receive lisinopril specifically because of its renal-protective mechanism [2].

Evidence Base: What the Landmark Trials Actually Showed

No head-to-head trial has randomized patients to rosuvastatin versus lisinopril, because the two drugs address distinct physiological targets. The evidence base for each drug is deep, but it is parallel, not comparative.

JUPITER: The Case for Rosuvastatin in Primary Prevention

The JUPITER trial (N=17,802) published in the New England Journal of Medicine in 2008 randomized adults with LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP at or above 2.0 mg/L) to rosuvastatin 20 mg daily or placebo [4]. The trial was stopped early at a median follow-up of 1.9 years.

Rosuvastatin reduced the primary composite endpoint of major cardiovascular events by 44% (hazard ratio 0.56; 95% CI 0.46 to 0.69; P<0.00001) [4]. All-cause mortality fell by 20%. LDL-C dropped from a median of 108 mg/dL to 55 mg/dL in the active arm, a 49% reduction.

The JUPITER finding reshaped statin prescribing by extending eligibility to patients with normal LDL-C but elevated inflammatory markers. It provided the key evidence base for rosuvastatin's role in primary prevention, which the ACC/AHA guidelines now codify [3].

ALLHAT: Lisinopril in a High-Risk Hypertensive Population

The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, N=33,357) compared chlorthalidone, amlodipine, and lisinopril in hypertensive adults aged 55 or older with at least one additional cardiovascular risk factor. Published in JAMA in 2002, ALLHAT found equivalent rates of fatal coronary heart disease and nonfatal MI across the three treatment arms [5].

Lisinopril showed slightly worse stroke prevention than chlorthalidone in Black participants (relative risk 1.40; 95% CI 1.14 to 1.73), an outcome the investigators attributed to smaller blood-pressure reductions in that subgroup [5]. Current AHA and JNC guidelines note this finding and often recommend thiazide diuretics or calcium channel blockers as first-line agents in Black patients with uncomplicated hypertension [6].

ALLHAT did not test rosuvastatin. The ALLHAT-LLT sub-study tested pravastatin against usual care, not rosuvastatin. Conflating the two drugs based on the same trial acronym is an error that appears in some competitor content.

What the Trials Cannot Tell You

Neither JUPITER nor ALLHAT provides data on switching one drug for the other, combining them at specific doses for synergistic benefit, or comparative cost-effectiveness. Observational analyses from insurance claims databases suggest that approximately 31% of U.S. Patients who initiate a statin are also taking an ACE inhibitor within 12 months, according to IQVIA data cited by the American Heart Association's 2023 Heart Disease and Stroke Statistics update [6]. The drugs are frequently co-prescribed, not compared.

Cost and Generic Access: A Detailed Breakdown

Cost is often the deciding factor in medication adherence. Both rosuvastatin and lisinopril are available as low-cost generics, but their pricing histories and access channels differ in practical ways.

Rosuvastatin (Generic Crestor): Pricing Since 2016

AstraZeneca's patent on branded Crestor expired in July 2016. Generic rosuvastatin entered the U.S. Market quickly. By mid-2017, multiple manufacturers were producing the generic, and prices fell sharply.

Current cash prices for rosuvastatin (as of 2025):

| Dose | 30-day supply (cash, GoodRx low) | 90-day supply | |------|----------------------------------|---------------| | 5 mg | $10, $18 | $22, $45 | | 10 mg | $10, $25 | $24, $55 | | 20 mg | $12, $30 | $28, $65 | | 40 mg | $15, $35 | $30, $75 |

Branded Crestor still costs $250, $350 per 30-day supply without insurance. No clinical reason supports choosing brand-name Crestor over generic rosuvastatin; the FDA requires bioequivalence within a 80 to 125% confidence interval for AUC and Cmax [7].

Lisinopril: Among the Cheapest Drugs on the Market

Lisinopril has been generic since the early 1990s and is one of the most widely dispensed drugs in the United States. The CDC reports it consistently ranks in the top five most-prescribed outpatient medications nationally [8].

Current cash prices for lisinopril:

| Dose | 30-day supply (cash, GoodRx low) | 90-day supply | |------|----------------------------------|---------------| | 5 mg | $4, $10 | $9, $22 | | 10 mg | $4, $12 | $9, $25 | | 20 mg | $5, $14 | $10, $28 | | 40 mg | $6, $16 | $12, $35 |

Many national pharmacy chains (Walmart, Kroger, Publix) include lisinopril on their $4 generic lists. At some locations, a 30-day supply costs less than a single dose co-pay under many insurance plans.

Insurance and Medicare Coverage

Both drugs appear on virtually every commercial formulary and on Medicare Part D formularies as Tier 1 (preferred generic) or Tier 2 agents. A 2023 analysis of Medicare Part D formularies found rosuvastatin covered at Tier 1 in 89% of stand-alone prescription drug plans and lisinopril at Tier 1 in 97% of plans [9].

Patients who remain uninsured should use GoodRx, Mark Cuban's Cost Plus Drugs (costplusdrugs.com), or manufacturer patient-assistance programs. AstraZeneca maintains an AZ&Me Prescription Savings program for branded Crestor, though the program's financial threshold for qualification changed in 2024.

Telehealth Prescribing and Access

Both drugs require a prescription, but telehealth platforms have made obtaining that prescription substantially faster. HealthRX prescribers can evaluate lipid panels and blood-pressure readings submitted electronically and issue prescriptions, which are then routed to the patient's preferred pharmacy or shipped via mail-order.

For rosuvastatin, baseline lipid panel results and a 10-year ASCVD risk calculation are typically required before prescribing. For lisinopril, at-home blood-pressure readings across at least two separate days, along with basic metabolic panel results (to assess creatinine and potassium), are standard pre-prescribing requirements under ACC/AHA protocols [3].

Side-Effect Profiles: What Changes Your Cost-Benefit Calculation

Price only matters if the drug is tolerable. Rosuvastatin and lisinopril have distinct adverse-effect profiles, and switching from one to the other because of side effects is not a valid strategy since they treat different conditions.

Rosuvastatin Side Effects

Myalgia (muscle aching without CK elevation) is the most common reason patients discontinue statins, affecting roughly 5 to 10% in clinical trials but as many as 15 to 20% in observational registry data. The SAMSON trial (N=60, crossover) found that 90% of statin-attributed muscle symptoms were nocebo in origin rather than pharmacological [10]. True statin-induced myopathy with CK elevation above 10 times the upper limit of normal is rare, occurring in fewer than 1 per 10,000 patient-years.

Rosuvastatin at 40 mg daily carries a small but measurable increased risk of new-onset type 2 diabetes (approximately 0.1% absolute risk increase per year in high-risk populations) [4]. Transaminase elevations above three times the upper limit of normal occur in fewer than 1% of patients.

Lisinopril Side Effects

A dry, nonproductive cough occurs in 10 to 15% of patients taking any ACE inhibitor, including lisinopril, due to bradykinin accumulation. The cough resolves within one to four weeks of stopping the drug. Angioedema is rarer (0.1 to 0.7%) but can be life-threatening and is an absolute contraindication to restarting any ACE inhibitor.

Hyperkalemia is a clinically significant concern, especially in patients with chronic kidney disease or those taking potassium-sparing diuretics or NSAIDs. A baseline potassium above 5.0 mEq/L generally warrants dose reduction or an alternative agent [2]. First-dose hypotension, particularly in volume-depleted patients, can cause syncope; the standard approach is to start at 5 mg daily and titrate upward.

When Both Drugs Are Prescribed Together

The co-prescription of a statin and an ACE inhibitor is common in patients who have both dyslipidemia and hypertension, two conditions that frequently coexist. A useful clinical decision framework for determining whether a patient needs one drug, the other, or both involves three questions:

1. Is LDL-C above the guideline threshold for the patient's risk category? Per the 2019 ACC/AHA guidelines, a patient with 10-year ASCVD risk at or above 7.5% and LDL-C at or above 70 mg/dL is a candidate for statin therapy. If yes, rosuvastatin (or another statin) belongs on the list [3].

2. Is blood pressure at or above 130/80 mmHg on two separate readings? If yes, and if the patient does not have a compelling indication for a different drug class (e.g., Black race and uncomplicated hypertension, where a thiazide or CCB may be preferred), lisinopril is a reasonable first-line choice [5].

3. Are there additional compelling indications? Patients with heart failure with reduced ejection fraction benefit from both a statin (for underlying atherosclerotic disease risk reduction) and an ACE inhibitor (for mortality reduction in HFrEF). Post-MI patients frequently receive both drugs as part of secondary prevention protocols. Diabetic patients with microalbuminuria may receive lisinopril specifically to slow kidney disease progression, independently of blood-pressure control.

No interaction of clinical significance exists between rosuvastatin and lisinopril. They do not share metabolic pathways, do not affect each other's plasma concentrations, and are safe to take simultaneously. Pill burden is the main practical concern, which is why some patients prefer combination cardiovascular pill packs.

Switching Between These Drugs: When It Does and Does Not Apply

Patients sometimes ask whether they can switch from rosuvastatin to lisinopril or vice versa. The short answer is no, not as a direct substitution, because the drugs address different problems.

Situations That Might Prompt a Medication Change

A patient on rosuvastatin who develops statin-associated muscle symptoms may be switched to a lower-potency statin (e.g., pravastatin or fluvastatin) or a non-statin alternative (ezetimibe, bempedoic acid, or a PCSK9 inhibitor). Lisinopril is not a replacement for statin therapy under any guideline.

A patient on lisinopril who develops ACE-inhibitor cough is typically switched to an angiotensin receptor blocker (ARB), most commonly losartan or valsartan, which block the angiotensin II receptor downstream without causing bradykinin accumulation. Rosuvastatin is not a replacement for antihypertensive therapy.

The Only Overlap Scenario

The one clinical scenario where the choice of one might affect decisions about the other is in a patient with borderline cardiovascular risk who has both mildly elevated LDL-C and mildly elevated blood pressure. Some guidelines allow a clinician to prioritize whichever risk factor is higher. If a patient's 10-year ASCVD risk is 7.9% driven mostly by hypertension, treating blood pressure first with lisinopril and re-assessing ASCVD risk at three months is a defensible strategy. The 2019 ACC/AHA Primary Prevention Guideline explicitly endorses a risk-discussion approach before initiating statin therapy in the 7.5 to 10% intermediate-risk range [3].

Regulatory Status and FDA Approvals

Rosuvastatin calcium received FDA approval on August 12, 2003, for treatment of primary hyperlipidemia and mixed dyslipidemia [1]. The approved dose range is 5 to 40 mg once daily. The 40 mg dose is reserved for patients who do not achieve adequate LDL-C reduction on 20 mg, and the FDA labeling notes that the 40 mg dose was associated with a higher rate of myopathy in Asian patients.

Lisinopril received initial FDA approval in 1987 for hypertension and later for adjunctive therapy in heart failure and acute MI [2]. Two brand names have existed historically: Prinivil (Merck) and Zestril (AstraZeneca), both now largely replaced by generics. The approved dose range for hypertension is 10 to 40 mg once daily; for heart failure, 5 to 40 mg once daily with slower titration.

Both drugs are Category D for pregnancy. Lisinopril is absolutely contraindicated in the second and third trimesters due to fetal renal toxicity; rosuvastatin is contraindicated throughout pregnancy due to potential teratogenicity. Women of reproductive age on either drug require effective contraception and counseling.

Guideline Positions on Both Drugs

The 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease states directly: "For patients with clinical ASCVD, high-intensity statin therapy should be initiated or continued to achieve a 50% or greater reduction in LDL-C." [3] Rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg are the two agents classified as high-intensity statins by that guideline.

Regarding antihypertensives, the 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults defines Stage 1 hypertension as systolic blood pressure of 130 to 139 mmHg or diastolic 80 to 89 mmHg and recommends drug therapy for Stage 1 patients with 10-year ASCVD risk at or above 10% [6]. The guideline does not rank ACE inhibitors above ARBs, thiazides, or calcium channel blockers for most patients, but notes the specific evidence base for ACE inhibitors in diabetes and chronic kidney disease.

The American Diabetes Association's Standards of Care 2024 recommend ACE inhibitors or ARBs as preferred antihypertensive agents for people with diabetes who have albuminuria, blood pressure above 130/80 mmHg, or both [11]. The same document recommends moderate-to-high-intensity statin therapy for all adults with diabetes aged 40 to 75 years regardless of baseline LDL-C.

Practical Access Channels in 2025

Pharmacy Options

Rosuvastatin and lisinopril are stocked at essentially every U.S. Pharmacy. The most cost-effective channels in 2025 are:

1. Mark Cuban's Cost Plus Drugs: rosuvastatin 10 mg, 90 tablets, approximately $14; lisinopril 10 mg, 90 tablets, approximately $6.
2. GoodRx coupons at chain pharmacies (CVS, Walgreens, Rite Aid): prices vary by zip code but typically $10, $30 per 30-day supply for rosuvastatin and $4, $12 for lisinopril.
3. Walmart $4 generic program: lisinopril is consistently included; rosuvastatin is included at some locations.
4. NeedyMeds.org and RxAssist: free programs for patients below 200% of the federal poverty level.

Telehealth-Specific Considerations

Most telehealth platforms, including HealthRX, can prescribe both drugs after an asynchronous visit. Requirements for rosuvastatin typically include a recent lipid panel (within 12 months), documentation of cardiovascular risk, and a brief questionnaire covering liver disease, pregnancy status, and current medications. Lisinopril requirements include recent blood-pressure readings, serum creatinine, and serum potassium. Both drugs can be prescribed as 90-day supplies to reduce refill frequency and lower per-unit cost.